ArticleCureus2020
Stevens Johnson Syndrome in a Patient with Giant Cell Arteritis During Short Term Tocilizumab Therapy.
Article in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 5 citations in OpenAlex.
- Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.Drugs · 2026Review
- Rapid progression to toxic epidermal necrolysis following switch of PD-1 inhibitors: a case report.Frontiers in medicine · 2026Article
- Drug-induced Tongue Disorders: A Comprehensive Literature Review.Current drug safety · 2025Review
- Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report.Journal of inflammation research · 2023Article
- Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature.World journal of clinical cases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report represents a rare life-threatening hypersensitivity reaction of tocilizumab drug when it is used to treat giant cell arteritis. An elderly female with history of bilateral giant cell arteritis with anterior ischemic optic neuropathy of the right eye was started on tocilizumab after developing glucocorticoid-related complications. She received one month of the tocilizumab therapy along with the prednisone taper. The patient initially developed sinus and mucosal edema, presented as drooling with mild tongue and lip swelling. It eventually progressed into development of new onset of erythematous macules and flaccid bullae which was biopsy-confirmed Stevens Johnson syndrome. Tocilizumab drug was immediately discontinued and she was treated with supportive care. The goal of this report is to present the first detailed case of presumed tocilizumab-induced Steven Johnson syndrome which emphasizes the importance of post-marketing surveillance and collection of data on adverse events of this drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.